NeurologicalICD-10: G47.4Affects about 1 in 2,000 people in the United States

Narcolepsy

Also known as: Narcolepsy Type 1, Narcolepsy Type 2

Narcolepsy is a chronic neurological disorder that impairs the brain's ability to regulate sleep-wake cycles, causing overwhelming daytime drowsiness and sudden attacks of sleep. Type 1 narcolepsy includes cataplexy (sudden loss of muscle tone triggered by emotions), while Type 2 does not. The condition is caused by a deficiency of the neurotransmitter hypocretin (orexin) and typically begins in childhood or young adulthood.

Last updated November 10, 2026

Understanding Narcolepsy

Narcolepsy is a lifelong neurological disorder in which the boundary between wakefulness and sleep, and particularly REM sleep, breaks down, so that irresistible sleepiness invades the day and fragments of dreaming sleep (paralysis, hallucinations, sudden muscle weakness) intrude into waking life. Type 1, defined by cataplexy or a measured deficiency of the brain peptide hypocretin, affects about 25 to 50 people per 100,000; type 2, without cataplexy, is probably as common but less well counted. Together they affect an estimated 135,000 to 200,000 Americans, though fewer than half have been diagnosed. Symptoms usually begin between 10 and 25, with a second smaller peak in the mid-30s, and the average gap between first symptoms and diagnosis is still 8 to 15 years, during which people are commonly labeled lazy, depressed, epileptic or simply short of sleep. Men and women are affected equally, and about a third of people with type 1 also have obesity, which develops rapidly around onset.

In type 1 narcolepsy, 85 to 95 percent of the roughly 70,000 neurons in the lateral hypothalamus that make hypocretin (also called orexin) have been destroyed. Hypocretin is the brain's main stabilizer of wakefulness; without it the switch between wake, non-REM and REM sleep flickers, which explains why people fall asleep within minutes whatever they are doing and why REM features appear at the wrong time. The loss is almost certainly autoimmune: 98 percent of people with type 1 carry the HLA-DQB1*06:02 immune gene variant, compared with 12 to 38 percent of the general population, hypocretin-reactive T cells have been found in patients' blood, and cases spiked after the 2009 H1N1 influenza pandemic in China and after one adjuvanted H1N1 vaccine, Pandemrix, in Scandinavia. Why type 2 occurs is less clear; hypocretin levels are usually normal and some cases later develop cataplexy. Narcolepsy does not shorten life, but nighttime sleep is paradoxically broken, and depression, anxiety, sleep apnea, restless legs and metabolic problems are all more common than in the general population.

Diagnosis rests on an overnight polysomnogram followed by a Multiple Sleep Latency Test (MSLT); falling asleep in an average of 8 minutes or less with REM sleep appearing in at least two naps meets the criteria. The test is only valid after a week or more of adequate sleep and off REM-suppressing antidepressants for at least two weeks, stopped only under the sleep physician's plan because withdrawal can provoke a surge of cataplexy. A spinal fluid hypocretin-1 level of 110 pg/mL or below confirms type 1. The 2021 American Academy of Sleep Medicine guideline strongly recommends four drugs. Modafinil lowers Epworth sleepiness scores by about 4 to 5 points, and pitolisant matched it in the 95-person HARMONY I trial while cutting cataplexy by 75 percent in a second. Sodium oxybate is the most effective treatment for cataplexy and broken night sleep, cutting weekly attacks by roughly two-thirds at 9 g. Solriamfetol added 10 to 12 minutes of objective wakefulness in a 239-person trial, and hypocretin receptor agonists have shown large effects in late-stage trials.

This is a condition where honesty about supplements matters, because the marketing is loud and the evidence is almost empty. There is one randomized, placebo-controlled trial of any natural product in narcolepsy: in 30 Japanese patients with type 1, 510 mg of L-carnitine daily for 8 weeks reduced total time spent dozing during the day on sleep diaries, though Epworth scores did not change significantly and the result has not been replicated. Vitamin D levels are lower in people with narcolepsy in several studies, which justifies checking and correcting a deficiency, but no trial has shown supplementation changes sleepiness. Caffeine is the one widely used wake-promoting substance with real pharmacology, but it has no narcolepsy trials and its effect is small next to prescription drugs. Melatonin, B vitamins, ginseng, rhodiola, tyrosine, ashwagandha and cannabidiol have no trials in narcolepsy at all, and sedating products such as valerian, kava, high-dose melatonin and antihistamine sleep aids can deepen daytime sleepiness and are best avoided. Supplements are not a reason to delay a sleep study.

The most common mistake is trying to fix narcolepsy with more sleep. Sleeping 10 or 12 hours, lying in at weekends and dozing whenever possible does not restore alertness, because the problem is wake stability, not sleep debt, and irregular hours make both daytime sleepiness and nighttime fragmentation worse. The approach that works is a fixed schedule with 7.5 to 8 hours in bed and one or two planned 15 to 20 minute naps at the same times each day, which trials show reduce unplanned sleep attacks more than ad-hoc dozing. The second mistake is stacking caffeine and energy drinks through the afternoon and evening to compensate, which fragments the already-broken night and leaves the person sleepier the next day. The third, and the most dangerous, is driving while sleepy: people with untreated narcolepsy have roughly a three to four-fold higher crash rate, and a nap before driving, trips under an hour and a frank conversation with your sleep physician about fitness to drive are not optional.

At a Glance

Common symptoms
Excessive daytime sleepiness despite adequate nighttime sleep, Sudden sleep attacks at inappropriate times, Cataplexy — sudden muscle weakness triggered by laughter or strong emotion (Type 1)
Main treatments
Wake-promoting agents (modafinil, armodafinil, solriamfetol), Sodium oxybate (Xyrem) for cataplexy and disrupted nighttime sleep, Pitolisant (histamine-3 receptor inverse agonist)
Category
Neurological · Affects about 1 in 2,000 people in the United States
See a doctor if
Persistent excessive daytime sleepiness interfering with work or school

Symptoms

Excessive daytime sleepiness despite adequate nighttime sleep
Sudden sleep attacks at inappropriate times
Cataplexy — sudden muscle weakness triggered by laughter or strong emotion (Type 1)
Sleep paralysis (inability to move or speak while falling asleep or waking up)
Hypnagogic or hypnopompic hallucinations
Fragmented nighttime sleep
Automatic behaviors (continuing tasks without awareness)

Causes

  • Loss of hypocretin (orexin)-producing neurons in the hypothalamus
  • Autoimmune destruction possibly triggered by infection (H1N1, streptococcus)
  • Genetic factors (strong association with HLA-DQB1*0602)
  • Rarely, brain injuries or tumors affecting the hypothalamus

Risk Factors

  • Family history of narcolepsy
  • Age 10–30 at symptom onset
  • Carrying the HLA-DQB1*0602 gene variant
  • History of certain infections (H1N1 influenza, streptococcal infections)

Diagnosis

  • Polysomnography (overnight sleep study)
  • Multiple Sleep Latency Test (MSLT) showing rapid-onset REM sleep
  • Measurement of hypocretin levels in cerebrospinal fluid (for Type 1)
  • Sleep diary and Epworth Sleepiness Scale assessment

Treatment

  • Wake-promoting agents (modafinil, armodafinil, solriamfetol)
  • Sodium oxybate (Xyrem) for cataplexy and disrupted nighttime sleep
  • Pitolisant (histamine-3 receptor inverse agonist)
  • Scheduled short naps during the day
  • Antidepressants (venlafaxine, fluoxetine) for cataplexy in some patients
  • Lifestyle modifications (regular sleep schedule, good sleep hygiene)

Natural remedies for narcolepsy: what the evidence says

Ranked by the strength of human evidence for narcolepsy specifically. These sit alongside medical care, not in place of it.

  1. L-Carnitine

    Preliminary evidence

    People with type 1 narcolepsy have been found to have low blood acylcarnitine levels linked to a variant in the CPT1B gene, which led to a randomized, double-blind, crossover trial in 30 Japanese patients. Eight weeks of 510 mg L-carnitine daily reduced the total time spent dozing during the daytime on sleep diaries compared with placebo, although Epworth Sleepiness Scale scores did not differ significantly. This single small trial has not been repeated, so the evidence is preliminary and the effect, if real, is modest.

    Studied dose
    510 mg L-carnitine daily (the studied dose), taken in the morning, for 8 weeks to judge any effect.
    Cautions
    Can cause nausea, a fishy body odor and, in people with seizure disorders, possibly more seizures. May increase the effect of warfarin. Avoid in untreated hypothyroidism; discuss with your sleep physician rather than self-prescribing.
  2. Vitamin D

    Preliminary evidence

    Several studies, including a French series comparing type 1 narcolepsy patients with matched controls, found vitamin D deficiency more common in narcolepsy, and low vitamin D is associated with greater daytime sleepiness and fatigue in the general population. No trial has tested whether correcting it improves narcolepsy symptoms. Checking a 25-hydroxyvitamin D level and treating a deficiency is sensible for bone and general health, particularly given the higher rates of obesity and reduced daytime activity, not as a treatment for sleepiness.

    Studied dose
    1,000 to 2,000 IU vitamin D3 daily if levels are low, rechecked after 3 months.
    Cautions
    Doses above 4,000 IU daily without monitoring can raise blood calcium. Use caution with thiazide diuretics. No interaction with narcolepsy medications is known.

What matters day to day

  • Keep the same bedtime and wake time every day, including weekends, with 7.5 to 8 hours in bed: irregular hours worsen both daytime sleep attacks and the fragmented night sleep that is part of narcolepsy.
  • Schedule one or two 15 to 20 minute naps at fixed times, typically early afternoon and late afternoon: planned brief naps restore alertness for 1 to 3 hours and reduce unplanned sleep episodes more than napping on demand.
  • Keep caffeine to a maximum of about 400 mg a day and none after early afternoon: it gives a small lift but, taken late, deepens the night-time fragmentation that makes the next day worse.
  • Nap before any drive, keep trips under an hour, and pull over at the first sign of drowsiness: untreated narcolepsy carries a three to four-fold higher crash risk, and no amount of willpower overrides a sleep attack.
  • Exercise for 20 to 30 minutes most days, finishing at least 4 hours before bed: regular activity improves daytime alertness and helps counter the rapid weight gain that often accompanies type 1 onset.
  • Avoid alcohol in the evening and heavy carbohydrate lunches: both deepen post-meal sleepiness, and alcohol fragments sleep and can worsen cataplexy and sleep paralysis.

Prevention

  • No known prevention for narcolepsy
  • Early diagnosis and treatment can significantly improve quality of life

When to See a Doctor

  • Persistent excessive daytime sleepiness interfering with work or school
  • Episodes of sudden muscle weakness with strong emotions
  • Falling asleep involuntarily during activities like driving or talking
  • Sleep paralysis or vivid hallucinations during sleep transitions

Frequently Asked Questions

References

  1. Maski K, Trotti LM, Kotagal S, et al.. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine (2021)
  2. Scammell TE. Narcolepsy. New England Journal of Medicine (2015)
  3. Thannickal TC, Moore RY, Nienhuis R, et al.. Reduced number of hypocretin neurons in human narcolepsy. Neuron (2000)
  4. Dauvilliers Y, Bassetti C, Lammers GJ, et al.. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial (HARMONY I). The Lancet Neurology (2013)
  5. US Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep (2002)
  6. Thorpy MJ, Shapiro C, Mayer G, et al.. A randomized study of solriamfetol for excessive daytime sleepiness in narcolepsy. Annals of Neurology (2019)
  7. Miyagawa T, Kawamura H, Obuchi M, et al.. Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial. PLoS One (2013)
  8. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, et al.. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One (2012)
  9. National Institute of Neurological Disorders and Stroke. Narcolepsy (2024)View source
  10. MedlinePlus, National Library of Medicine. Narcolepsy (2024)View source

Related Conditions

Have questions about Narcolepsy?

Ask Mother Nature AI for personalized, evidence-based guidance.

Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.